[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.9.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1991

Evaluation of a Commercial Recombinant Tissue-Type Plasminogen Activator Preparation in the Subretinal Space of the Cat

Author Affiliations

From the Departments of Ophthalmology (Drs Benner, Toth, Morse and Landers), Biochemistry and Biophysics, and Biological Chemistry (Dr Hjelmeland), University of California, Davis, Sacramento.

Arch Ophthalmol. 1991;109(12):1731-1736. doi:10.1001/archopht.1991.01080120115039
Abstract

• To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue-type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40-to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue-type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor—retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue-type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.

×